Please use this identifier to cite or link to this item:
Título : Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer’s disease
Autor : Marco Contelles, José Luis, León, Rafael, de los Ríos, Cristóbal, Samadi, Abdelouahid, Bartolini, Manuela, Andrisano, Vincenza, Huertas, Oscar, Barril, Xavier, Luque, F. Javier, Rodríguez Franco, María Isabel, López, Beatriz, López, Manuela G., García, Antonio G., do Carmo Carreiras, María, Villarroya, Mercedes
Fecha de publicación : 2009
Editor: American Chemical Society
Resumen: Tacripyrines (1-14) have been designed by combining an AChE inhibitor (tacrine) with a calcium antagonist such as nimodipine and are targeted to develop a multitarget therapeutic strategy to confront AD. Tacripyrines are selective and potent AChE inhibitors in the nanomolar range. The mixed type inhibition of hAChE activity of compound 11 (IC50 105 ( 15 nM) is associated to a 30.7 ( 8.6% inhibition of the proaggregating action of AChE on the A and a moderate inhibition of A self-aggregation (34.9 ( 5.4%). Molecular modeling indicates that binding of compound 11 to the AChE PAS mainly involves the (R)-11 enantiomer, which also agrees with the noncompetitive inhibition mechanism exhibited by p-methoxytacripyrine 11. Tacripyrines are neuroprotective agents, show moderate Ca2+ channel blocking effect, and cross the blood-brain barrier, emerging as lead candidates for treating AD.
Versión del editor:
DOI: 10.1021/jm801292b
Citación : Journal of Medicinal Chemistry 52 : 2724–2732 (2009)
Appears in Collections:(IQM) Artículos

Files in This Item:
There are no files associated with this item.
Show full item record

Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.